Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
3d
News Medical on MSNCD2AP and Alzheimer’s disease: A key regulator of neurodegeneration and potential therapeutic targetA comprehensive Thought Leaders Invited Review in Brain Medicine highlights the crucial role of CD2-associated protein (CD2AP ...
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating ...
27 There were 52 proteins that showed associations with all 3 outcomes at a false‐discovery rate <0.05 threshold, of which MMP12 (matrix metalloproteinase ‐12), complement C1QTNF1(C1q tumor necrosis .
Anti-C1q antibodies were present among 74.3% of patients with immunoglobulin G4-related disease. Anti-C1q antibodies are highly prevalent among patients with immunoglobulin G4-related disease ...
Erythropoietin-producing hepatocellular (Eph) receptors, including EphA4, are expressed on the cell surface and involved in brain development, which involves extensive pruning of synapses. A variant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results